Plain-English translation of NCT05483491 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing KK-LC-1 TCR-T cell therapy, a personalized cancer treatment that takes your own immune cells, modifies them in the laboratory to recognize a specific protein found on certain cancers, and then returns them to your body to fight the disease. The study will determine the safest and most effective dose of this treatment and how well it works against advanced cancers of the stomach, breast, cervix, and lungs.
Many people with advanced gastric, breast, cervical, and lung cancers don't respond well to standard treatments or run out of options. This new treatment harnesses your body's own immune system in a way that hasn't been widely available before, offering hope for patients who need alternatives.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy drugs (cyclophosphamide and fludarabine) to prepare your body for the new cells. Then you will receive a single infusion of your modified immune cells, followed by additional medication () to help boost their activity. The study will monitor you closely for side effects, how your tumor responds, and how long the response lasts. Most of the active treatment happens over a few weeks, though follow-up visits will continue after that.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
Christian Hinrichs
Collaborators
National Cancer Institute (NCI), Iovance Biotherapeutics, Inc.
Enrollment target
~30 participants
Started
September 2022
Primary completion
September 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tobi Adewale
Rutgers Cancer Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.